You are here:

American Journal of Cancer Prevention

ISSN (Print): 2328-7322

ISSN (Online): 2328-7314

Website: http://www.sciepub.com/journal/AJCP

Current Issue» Volume 3, Number 2 (2015)

Article

Anti-proliferative, Cytotoxicity and Anti-oxidant Activity of Juglans regia Extract

1Department of Research, Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India

2Department of Botany, Benazeer College of science, Bhopal, India

3Department of Zoology, Benazeer College of Science and Commerce Bhopal, India


American Journal of Cancer Prevention. 2015, 3(2), 45-50
DOI: 10.12691/ajcp-3-2-4
Copyright © 2015 Science and Education Publishing

Cite this paper:
Tajamul Islam Shah, Ekta Sharma, Gowhar Ahmad Shah. Anti-proliferative, Cytotoxicity and Anti-oxidant Activity of Juglans regia Extract. American Journal of Cancer Prevention. 2015; 3(2):45-50. doi: 10.12691/ajcp-3-2-4.

Correspondence to: Tajamul  Islam Shah, Department of Research, Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India. Email: taju.zoology@gmail.com

Abstract

Objective: Juglans regia (walnuts), the royal species from Junglandaceae family, well-known for its valuable medicinal uses, their regular consumption may have beneficial effects against oxidative stress mediated diseases including cancer. The present study was aimed to explore the total phenolic content, anti-proliferative and anti-oxidant activity of Juglans regia leaves. Methods: The leaf powder was extracted using different solvents and subjected for phytochemical investigation. The total phenolic contents were determined by the Folin–Ciocalteu method. The extracts comprising a good amount of secondary metabolites especially polyphenols were used to evaluate their antioxidant activity using Fenton’s reagent reaction and DPPH scavenging assay, while cytotoxic and anti-proliferative activity against B16F10 mice melanoma and A375 human melanoma cell were screened using MTT Assay. Observation: Methanolic extract presented the highest total phenolic content (94.39 ± 5.63 mg of GAE/g of extract) as compared to aqueous extract (27.92 ± 1.40 mg of GAE/g of extract). Similarly, methanolic extract presented the highest antioxidant activity (EC50 of 0.250mg/ml) followed by water extract (EC50 of 0.325mg/ml) in Fenton’s reaction and 0.199 ± 0.023 and 2.991 ± 0.740, respectively in DPPH assay. The extracts showed concentration dependent growth inhibition activity (IC50 0.234 and 0.304mg/ml) against B16F10 mice melanoma and A375 human melanoma cell line (IC50 0.298 and 0.350mg/ml) respectively. The extracts proved least toxic when treated with normal lymphocytes. The results indicate that walnut leaves are an excellent source of antioxidant and anti-cancerous agents and may prove fruitful herbal remedy in near future. However, the extracts proved effective against mice melanoma and human melanoma cells. Despite, more study is required before coming to any conclusion.

Keywords

References

[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[
[1]  Block, G., Patterson, B., Subar, A., 1992. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr. Cancer 18, 1-29.
 
[2]  Heimendinger, J., Van Duyn, M.A., Chapelsky, D., Foerster, S., Stables, G., 1996. The national 5 A Day for Better Health Program: a large-scale nutrition intervention. J. Public Health Manag. Pract. 2, 27-35.
 
[3]  Reddy, L., Odhav, B., Bhoola, K.D., 2003. Natural products for cancer prevention: a global perspective. Pharmacol. Ther. 99, 1-13.
 
[4]  Mathew, A., Peters, U., Chatterjee, N., Kulldorff, M., Sinha, R., 2004. Fat, fiber, fruits, vegetables, and risk of colorectal adenomas. Int. J. Cancer 108, 287-292.
 
[5]  Jenab, M., Ferrari, P., Slimani, N., et al., 2004. Association of nut and seed intake with colorectal cancer risk in the European Prospective investigation into cancer and nutrition. Cancer Epidemiol. Biomarkers Prev. 13, 1595-1603.
 
Show More References
6]  Cao, G., Sofic, E., Prior, R., 1996. Antioxidant capacity of tea and common vegetables. J. Agr. Food Chem. 44, 3426-3431.
 
7]  Silva, B.M., Andrade, P.B., Valentão, P., Ferreres, F., Seabra, R.M., Ferreira, M.A., 2004. Quince (Cydonia oblonga Miller) seed (pulp, peel, and seed) and jam: antioxidant activity. J. Agr. Food Chem. 52, 4405-4712.
 
8]  Silva, B.M., Valentão, P., Seabra, R.M., Andrade, P.B., 2008. Quince (Cydonia oblonga Miller): an interesting dietary source of bioactive compounds. In: Papadopoulos, K.N. (Ed.), Food Chemistry Research Developments. Nova Science Publishers, Inc., New York, pp. 243-266.
 
9]  Giada, M.L., Filho, J.M., 2006. The importance of dietary phenolic compounds in the promotion of human health. Biol. Health Sci. 12, 7-15.
 
10]  Sun, J., Chu, Y.F., Wu, X., Liu, R., 2002. Antioxidant and antiproliferative activities of common seeds. J. Agr. Food Chem. 50, 7449-7454.
 
11]  Parry, J., SU, L., Moore, J., Cheng, Z., Lutner, M., Rao, J.N., Wang, J. Y., YU, L., 2006. Chemical compositions, antioxidant capacities, and antiproliferative activities of selected seed flours. J. Agr. Food Chem. 54, 3773-3778.
 
12]  Yang, J., Liu, R., Halim, L., 2009. Antioxidant and antiproliferative activities of common edible nut seeds. Food Sci. Technol. 42, 1-8.
 
13]  Blomhoff, R., Carlsen, M.,Andersen, L., Jacobs Jr., D., 2006. Health benefits of nuts: potential role of antioxidants. Br. J. Nutr. 96, S52–S60.
 
14]  Oliveira, I., Sousa, A., Ferreira, I., Bento, A., Estevinho, L., Pereira, J.A., 2008. Total phenols, antioxidant potential and antimicrobial activity of walnut (Juglans regia L.) green husks. Food Chem. Toxicol. 46, 2326-2331.
 
15]  Bruneton, J., 1999. Pharmacognosie, phytochimie, plantes médicinales. In: Technique et Documentation Lavoisier, Paris, pp. 418-419.
 
16]  Amaral, J., Seabra, R.M., Andrade, P.B., Valentão, P., Pereira, J.A., Ferreres, F., 2004.Phenolic profile in the quality control of walnut (Juglans regia L.) leaves. Food Chem. 88, 373-379.
 
17]  Pereira, J.A., Oliveira, I., Sousa, A., Valentão, P., Andrade, P.B., Ferreira, I., Ferreres, F., Bento, A., Seabra, R.M., Estevinho, L., 2007. Walnut (Juglans regia L.) leaves: phenolic compounds, antibacterial activity and antioxidant potential of different cultivars. Food Chem. Toxicol. 45, 2287-2295.
 
18]  Pereira, J.A., Oliveira, I., Sousa, A., Ferreira, I., Bento, A., Estevinho, L., 2008. Bioactive properties and chemical composition of six walnut (Juglans regia L.) cultivars. Food Chem. Toxicol. 46, 2103-2111.
 
19]  Singleton, V.L., Rossi, J.A.Jr., 1965. Colorimetry of total phenolics with phosphomolybdic-phosphotungstic acid reagents. Am. J. Enol. Viticult. 16, 144-158.
 
20]  Shah, T.I., Akthar, S., Ganesh, N., 2013. Prelimnary phytochemical evaluation and anti-bacterial potential of different leaf extracts of J. regia: A ubiquitous dry fruit from Kashmir-India. Pharm. Sci. Rev. Res., 19(2), Mar-Apr 2013; n0 18, 93-96.
 
21]  Almeida, I., Fernandes, E., Lima, J., Costa, P., Bahia, M.F., 2008. Walnut (Juglans regia) leaf extracts are strong scavengers of pro-oxidant reactive species. Food Chem. 106, 1014-1020.
 
22]  Hatano, T., Kagawa, H., Yasuhara, T., Okuda, T., 1988. Two new flavonoids and other constituents in licorice root: their relative astringency and scavenging effects. Chem. Pharm. Bull. 36, 2090-2097.
 
23]  Chen, C.Y., Blumberg, J.B., 2008. Phytochemical composition of nuts. Asia Pac. J. Clin. Nutr. 17, 329-332.
 
24]  Fukuda, T., Ito, H., Yoshida, T., 2003. Antioxidative polyphenols from walnuts (Juglans regia L.). Phytochemistry 63, 795-801.
 
25]  Khandelwal KR, 2005. Practical Pharmacognocy 16th ed. Pune: Nirali Prakashan.
 
26]  Umadevi P., A. Ganasoundari, B.S. Rao and K.K.Srinivasan. 1999. In vivo radioprotection by Ocimum flavanoids: survival of mice. Radiat. Res, 151 (1), 74-78.
 
27]  Kaur, K., Michael, H., Arora, S., Härkönen, P.L., Kumar, S., 2003. Studies on correlation of antimutagenic and antiproliferative activities of Juglans regia L.. J. Environ. Pathol. Toxicol. Oncol. 22, 59-67.
 
28]  Fleshner, N.E., 2002. Vitamin E and prostate cancer. Urol. Clin. North Am. 29, 107-113.
 
29]  Spaccarotella, K.J., Kris-Etherton, P.M., Stone, W.L., Bagshaw, D.M., Fishell, V.K., West, S.G., Lawrence, F.R., Hartman, T.J., 2008. The effect of walnut intake on factors related to prostate and vascular health in older men. Nutr. J. 2, 7-13.
 
30]  Bradford, P.G., Awad, A.B., 2007. Phytosterols as anticancer compounds. Mol. Nutr. Food Res. 51, 161-170.
 
31]  Han, D.H., Lee, M.J., Kim, J.H., 2006. Antioxidant and apoptosis-inducing activities of ellagic acid. Anticancer Res. 26, 3601–3606.
 
32]  Losso, J.N., Bansode, R.R., Trappey, A., Bawadi, H.A., Truax, R., 2004. In vitro anti- proliferative activities of ellagic acid. J. Nutr. Biochem. 15, 672-678.
 
33]  Yáñez, J., Vicente, V., Alcaraz, M., Catillo, J., Benavente-García, O., Canteras, M., Teruel, J., 2004. Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines: relationship between structure and activity. Nutr. Cancer 49, 191-199.
 
34]  Kawaii, S., Tomono, Y., Katase, E., Ogawa, K., Yano, M., 1999. Antiproliferative activity of flavonoids on several cancer cell lines. Biosci. Biotechnol. Biochem. 63, 896-899.
 
35]  Bhuvaneswari, V., Nagini, S., 2005. Lycopene: a review of its potential as an anticancer agent. Curr. Med. Chem. Anticancer Agents 5, 627-635.
 
36]  Srinivasan, V., Spence, D.W., Pandi-Perumal, S.R., Trakht, I., Cardinali, D.P., 2008. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr. Cancer Ther. 7, 189-203.
 
37]  Fiorentino, A., D’Abrosca, B., Pacifico, S., Mastellone, C., Piscopo, V., Caputo, R., Monaco, P., 2008. Isolation and structure elucidation of antioxidant polyphenols from quince (Cydonia vulgaris) peels. J. Agr. Food Chem. 56, 2660-2667.
 
38]  Zhang, Y., Seeram, N.P., Lee, R., Feng, L., Heber, D., 2008. Isolation and identification of straw berry phenolics with antioxidant and human cancer cell antiproliferative properties. J. Agr. Food Chem. 56, 670-675.
 
39]  Mertens-Talcott, S.U., Lee, H., Percival, S.S., Talcott, S.T., 2006. Induction of cell death in Caco-2 human colon carcinoma cells by ellagic acid rich fractions from muscadine grapes (Vitis rotundifolia). J. Agr. Food Chem. 54, 5336-5343.
 
40]  Russo, G.L., 2007. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem. Pharmacol. 74, 533-544.
 
41]  Bonfili, L., Cecarini, V., Amici, M., Cuccioloni, M., Angeletti, M., Keller, J.N., Eleuteri, A.M., 2008. Natural polyphenols as proteasome modulators and their role as anticancer compounds. FEBS J. 275, 5512-5526.
 
42]  Fresco, P., Borges, F., Diniz, C., Marques, M.P., 2006. New insights on the anticancer properties of dietary polyphenols. Med. Res. Rev. 26, 747-766.
 
43]  Liu, R.H., 2003. Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am. J. Clin. Nutr. 78, 517-520.
 
Show Less References

Article

Quality of Life of Patients Undergoing Cancer Treatment in B.P. Koirala Memorial Cancer Hospital, Bharatpur, Chitwan, Nepal

1Nursing Department, Kathmandu University School of Medical Sciences, Dhulikhel Hospital Kathmandu University Hospital, Dhulikhel, Nepal

2Chitwan Medical College, Bharatpur, Chitwan, Nepal


American Journal of Cancer Prevention. 2015, 3(2), 35-44
DOI: 10.12691/ajcp-3-2-3
Copyright © 2015 Science and Education Publishing

Cite this paper:
Radha Acharya Pandey, Govinda Prasad Dhungana, Jyotsana Twi Twi, Sudeepa Byanju, Barsha Khawas. Quality of Life of Patients Undergoing Cancer Treatment in B.P. Koirala Memorial Cancer Hospital, Bharatpur, Chitwan, Nepal. American Journal of Cancer Prevention. 2015; 3(2):35-44. doi: 10.12691/ajcp-3-2-3.

Correspondence to: Radha  Acharya Pandey, Nursing Department, Kathmandu University School of Medical Sciences, Dhulikhel Hospital Kathmandu University Hospital, Dhulikhel, Nepal. Email: radhapnd@yahoo.com

Abstract

This research entitled “Quality of Life of Patients Undergoing Cancer Treatment in B.P. Koirala Memorial Cancer Hospital, Bharatpur, Chitwan” was conducted to assess the quality of life of cancer patients. It was carried out among patients attending B. P. Koirala Memorial Cancer Hospital, Bharatpur, Chitwan. Background: In patients with different type of cancers and the quality of life (QoL) improvement is the main goal, since survival can be prolonged marginally. A diagnosis is very stressful for people, affecting all aspects of their being and quality of life. Up to date, knowledge on QoL impairments throughout the entire treatment process, often including several treatment modalities is scarce. One objective of this study was to assess the quality of life of cancer patient undergoing cancer treatment. Methods: A quantitative, cross-sectional, descriptive, design was adapted. A total of 245 cancer patients above 20 years old, were enrolled in the studies during August-September, 2013. Inclusion criteria were patients who had already received at least one type of cancer treatment and had attended the hospital for receiving the same or next type of treatment again. Exclusion criteria were any other chronic co-morbidity condition that could be influenced their QoL. The most commonly listed medical co-morbidities were: diabetes mellitus, hypertension, coronary artery disease. Cancer patients who have Eastern Co-operative Oncology Group (ECOG) performance status of 4 (i.e. fully bed-ridden) were excluded from the study. The data was collected by interview, using modified, structured scale of European Organization for Research and Treatment of Cancer Quality of life Questionnaire (EORTC QLQ- C30), prepared by the EORTC group. Information about the patient’s disease condition and treatment were obtained from the patient’s medical records. The collected data was analyzed by using SPSS version 16. Descriptive and inferential statistics were used to describe the respondent’s quality of life (QoL) scores and to identify the factors affecting it respectively. Results: The study findings revealed the quality of life of cancer patients to be influenced by many factors such as: site of cancer, stage of cancer, time elapsed since diagnosis and Eastern Co-operative Oncology Group (ECOG) performance status. The average QoL scores (out of 100) for different scales were 85.54 (global health/QoL), 77.03 (functional), and 16.14 (symptom). Loss of appetite was the most frequent complaint (mean = 20.27) and was present in almost all the patients. As the overall QoL of the patients was significantly correlated with different QoL scales as-, cognitive, emotional, physical, social, role functioning, pain, fatigue, dyspnoea, loss of appetite and nausea/vomiting and financial problem. Conclusion: Hence, in average, the quality of life of cancer patients was found to be relatively better, although there were higher ratings for some (as: cognitive, physical, role and emotional functioning) and lower for others (like social functioning). Additional research should be done in this area for improving the quality of life of specific type of cancer patients in Nepal, though the findings of this study are expected to provide the baseline knowledge regarding it.

Keywords

References

[[[[[[[[[[[[[[[[[[[[[[[[[[[[[
[1]  Global Health Observatory (GHO, 2012). Cancer mortality and morbidity. Available at www.who.org. (retrieved on 26th june, 2013).
 
[2]  American Cancer Society (2013). Cancer Facts & Figures 2013. Annual report (2013). Available at wrongdiagnosis.com. (Retrieved on 2nd July, 2013).
 
[3]  World Health Organization, (2006). Focus in Priorities, WHO Report 2005, Available at www.who.org. (Retrieved on 26th June, 2013).
 
[4]  Annual Report, B.P. Koirala Memorial Cancer Hospital, Bharatpur, Nepal, 2010.
 
[5]  Sajid, MS., Tonsi, A., & Baig, MK. (2008). Health-related quality of life measurement. Int J Health Care Qual Assur. 21(4), 365-73.
 
Show More References
6]  Aaronson, NK., Ahmedzai, S., & Bergman, B., (1993). The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 85, 365-376.
 
7]  Ahmedzai, N. S., Bergman, B., Bullinger, M., Cull, A., & Duez, N.J. (1993). The European Organization for Research and Treatment of Cancer QLQ-30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85(5), 365-76.
 
8]  Testa, MA., & Simonson, DC. (2009). Assessments of quality-of-life outcomes. N Engl J Med 334, 835-4.
 
9]  Maryam, Farooqui., Mohamed, Azmi. Hassali., Aishah, Knight., Asrul, Akmal. Shafie., Fahad, Saleem., Muhammad, Aslam. Farooqui., Hisham, Aljadhey.,(2013). Cross Sectional Assessment Health Related Quality of Life among Patients with Cancer in Malaysia. Asian Pacific Journal of Cancer prevention, 14 (5), 3017-3021.
 
10]  Carlos, k. H. Wong., Cindy, l. K. Lam., jensen, t. C. Poon., & dora, l. W. Kwong. (2013).clinical indicators of depression among ambulatory cancer patients undergoing chemotherapy. Japanese journal of clinical oncology.10, 334-337.
 
11]  World Health Organization, (2009). Focus in Priorities, WHO Report 2008, Available at www.who.org. (Retrieved on 26th June, 2011).
 
12]  Zhen, Gou, J., Zheng, Y., Qian, JX., Gu, XQ. & Wang JJ. (2013). Study on factors affecting the quality of life to cancer patients at the community level in Shaghai. Zhonghua Liu Xing Bing Xue Za Zhi, 26 (100), 761-6 (Retrieved on 20th September, 2013).
 
13]  Andrade, V., Sawada, N.O., & Barichello, E. (2011). Quality of life in hematologic oncology patients undergoing chemotherapy. Medical Journal of Malayasia, 66, (2) 84-87.
 
14]  Bahar, Mahjoubi., Rezvan, -Mirzaei., and Leila, Zahedi-Shoolami.(2012). A cross-sectional survey of quality of life in colostomates. Health Qual Life Outcomes, 10,136.
 
15]  Lim, G. (2011). Health related quality of life among patients with cancer. ASEAN J Psychiatry, 13 (1), 210-14.
 
16]  Golden, Masika., Lena, Wettergren., Thecla, W. Kohi., & Louise von Essen (2012). "Health-related quality of life and needs of care and support of adult Tanzanians with cancer: a mixed-methods study" BioMed Central, 10, 90-94.
 
17]  Donald, P. B., Gupta, D., and Edgar D. S. (2012). Predicting survival in prostate cancer: the role of quality of life assessment. Support Care Cancer. 20(6), 1267-1274.
 
18]  Bottomley, A., & Therasse, p. (2005). Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet oncol. 3, 620-628.
 
19]  Johnsen A. (2009). Health related quality of life in a nationally representative sample of hematological patients. Eur. J. Haematol. 83 (92), 139-148. (PMC free article).
 
20]  Priscilla, D. (2011). Quality of life among patients with Hematological cancer. Medical Journal of Malayasia, 66, (2).
 
21]  Gupta, D., Braun, D.P., & Markman, M. (2013). Longitudinal health-related quality of life assessment: implications for prognosis in ovarian cancer.J Ovarian Res. 6, 17.
 
22]  Heydarnejad, MS., Dehkordi, G., Hassanpour, D., & Dehkordi, K. (2011). Factors Affecting Quality of Life in Cancer Patients Undergoing Chemotherapy. African Health Science Journal, 11(2), 266-270. Http://Www.Ncbinlm.
 
23]  Meyer, F., Fortin, A., Gelinas, M., Nabid, A., Brochet, F.,& Tetu, B. (2009). Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy. J Clin Oncol, 27, 2970-6.
 
24]  Güner, P., Ishikhan V., Komurcu, S., Il, S., Ozturk, B., Arpaci, F., & Ozet, A. (2006). Quality of life and socio demographic characteristics of patients with cancer in Turkey. Oncology.
 
25]  Damm K., Roeske, N., & Jacob, C. (2013). Health-related quality of life questionnaires in lung cancer trials: a systematic literature review. Health Econ Rev,13(3)11-15.
 
26]  Zhou, De-ming., Chu, Jin-wei., & Cheng, Xiao-lin. (2004). Factors affecting the health-related quality of life in lung cancer patients; Measured by EORTC QLQ-C30 QLQ-L13. Turkish respiratory journal, 4(2), 61-66.
 
27]  Rustoen, T., Moum, T., Wiklund, I. & Hanestad, BR. (2004). Quality of life in newly diagnosed cancer patients, Sigma Theta Tau International, Available at google.com. (Retrieved on 20th September, 2011).
 
28]  Toyama, Yoichi., Seiya, Yoshiida., Ryota Saito., Hiroaki, Kitamura., Norimitsu Okui., Ryo, Miyake.,….Katsuhiko, Yanaga. (2013). Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients’ quality of life. BiomedCentral.
 
29]  Nemati, M., Alhani, F.,,& Zandshahdi, R.(2013). 1st congress in quality of life. Tehran, Iran: Book of Abstracts. Quality of life in cancerous adolescences undergoing chemotherapy; p. 25.
 
30]  Rustøen, T., & Hope, S. (2004). Quality of life, two central issues for cancer patients: a theoretical analysis. Cancer Nurs. 18, 355-361.
 
31]  Esbensen, B. A., Osterlind, K., Roer, O. & Hallberg, R. (2004). Quality of life of elderly persons with newly diagnosed cancer. European Journal of Cancer Care (Engl).13(5), 443-53. Available at www.pubmed.gov (Retrieved on 21st June, 2011).
 
32]  Lee, H. L., Ku, N. P., Dow, W.j. & Pai, l. (2001). Factors related to quality of life in breast cancer patients receiving chemotherapy. Journal of nursing research, 9(3):57 - 68. Www.pubmed.gov. (retrieved on 23rd june, 2013).
 
33]  Gurm,BK., Stephen, J., & Mackenzie, G. (2008). Understanding Canadian Punjabi- speaking South Asian Women’s experience of breast cancer: qualitative study. Int J Nursing studies, 45, 266-76.
 
34]  Van den Beuken (2009). Quality of life and non pain symptoms in Patients with Cancer. Journal of Pain and symptom Management, 38(2), 216-33.
 
Show Less References

Article

Detection of BCL2 Polymorphism in Patient with Hepatocellular Carcinoma

1Microbiology Department, Faculty of Medicine, Miniauniversity

2Medical Biochemistry, Faculty of Medicine, Cairo University

3Biochemistry Department, Faculty of Pharmacy (Girls), Al-Azhar University

4Andcentral Administration for Pharmaceutical Affairs, Ministry Of Health


American Journal of Cancer Prevention. 2015, 3(2), 27-34
DOI: 10.12691/ajcp-3-2-2
Copyright © 2015 Science and Education Publishing

Cite this paper:
Mohamed Abdel-Hamid, Olfat Gamil Shaker, Doha El-Sayed Ellakwa, Eman Fathy Abdel-Maksoud. Detection of BCL2 Polymorphism in Patient with Hepatocellular Carcinoma. American Journal of Cancer Prevention. 2015; 3(2):27-34. doi: 10.12691/ajcp-3-2-2.

Correspondence to: Doha  El-Sayed Ellakwa, Biochemistry Department, Faculty of Pharmacy (Girls), Al-Azhar University. Email: profdoha@gmail.com

Abstract

Introduction: Despite advances in the knowledge of the molecular virology of hepatitis C virus (HCV), the mechanisms of hepatocellular injury in HCV infection are not completely understood. Hepatitis C viral infection (HCV) influences the susceptibility to apoptosis. This could lead to insufficient antiviral immune response and persistent viral infection. Aim of this study: Is to examine whether BCL-2 gene polymorphism at codon 43 (+127G/A or Ala43Thr) has an impact on development of hepatocellular carcinoma caused by chronic hepatitis C infection among Egyptian patients. Subjects and Methods: The study included three groups; group 1: composed of 30 patients with hepatocellular carcinoma (HCC), group 2 composed of 30 patients with chronic hepatitis C infection (CHC) and group 3 composed of 30 healthy subjects matching the same age and socioeconomic status were taken as a control group. Gene polymorphism of BCL2 (Ala43Thr) was evaluated by Restriction fragment length polymorphism (PCR-RFLP) techniqueand measured for all patients and controls. Results: The summed 43Thr genotype was more frequent and statistically significant in HCC patients as compared to control group. This genotype of BCL2 gene may inhibit the programmed cell death which leads to disturbance in tissue and cells homeostasis and reduction in immune regulation. This result leads to viral replication and HCV persistence. Moreover, virus produces variety of mechanisms to block genes participated in apoptosis. This mechanism proves that CHC patients who have 43Thr genotype are more susceptible to HCC. Correlation coefficients between AFP versus ALT and AST were statistically significant. Conclusion: The data investigated for the first time that BCL2 polymorphism is associated with the susceptibility to in Egyptian populations and might be used as molecular markers for evaluating risk. This study clearly demonstrated that CHCexhibit a deregulation of apoptosis with the disease progression. This provides an insight into the pathogenesis of chronic hepatitis C infection, and may contribute to the therapy.

Keywords

References

[[[[[[[[[[[[[[[
[1]  Akkız, H., Bayram, S., Bekar, A., et al. A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a case-control study. J Viral Hepat. 2011, 18:399-407.
 
[2]  Daniele, B., Bencivenga, A., Megna, AS., et al. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004, 127: S108-12.
 
[3]  Farinati, F., Marino, D., De, Giorgio, M., et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroentero 2006, 101: 524-32.
 
[4]  Furth, PA., Bar-Peled, U., Li, M., et al. Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model. Oncogene 1999, 18: 6589-96.
 
[5]  Greider, C., Chattopadhyay, A., Parkhurst, C., et al. BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases. Oncogene 2002, 21: 7765-75.
 
Show More References
6]  Hanafy, SM., Shehata, OH., Farahat, NM. Expression of apoptotic markers BCL-2 and bax in chronic hepatitis C virus patients. Clinical Biochemistry 2010, 43: 1112-1117.
 
7]  Holmes, JA., Desmond, PV. and Thompson, AJ. Does IL28B Genotyping Still have a Role in the Era of Direct-acting Antiviral Therapy for Chronic Hepatitis C Infection? J Viral Hepat. 2012, 19 (10): 677-684.
 
8]  Huang, D., Adams, J., Cory, S. The conserved N-terminal BH4 domain of BCL-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J 1998, 17:1029–39.
 
9]  Johansson, C., Castillejo-Lopez, C., Johanneson, B. Association analysis with microsatellite and SNP markers does not support the involvement of BCL-2 in systemic lupus erythematosus in Mexican and Swedish patients and their families. Genes Immun 2000, 1:380-5.
 
10]  Johnson, PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001, 5:145-59.
 
11]  Komaki, S., Kohno, M., Matsuura, N., et al. The polymorphic 43Thr BCL-2 protein confers relative resistance to autoimmunity: an analytical evaluation. Hum Genet. 1998, 103(4):435-440.
 
12]  Kvansakul, M. and Hinds, M G. Structural biology of the Bcl-2 family and its mimicry by viral proteins. Cell Death Dis. 2013, 4 (11): e909.
 
13]  Marcellin, P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999, 31:9–16.
 
14]  Mohamoud, YA., Mumtaz, GR., Riome, S., Miller, D. and Abu-Raddad, LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis.Bio Med Central Infectious Diseases 2013, 13:288.
 
15]  Niederau, C., Lange, S., Heintges, T., et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998, 28: 1687–95.
 
16]  Seeff, LB. Natural history of hepatitis C. Hepatology 2002, 36(Suppl 1):S35–46.
 
17]  Song, P., Gao, J., Inagaki, Y., et al. Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatocellular Carcinoma in Japan and China. Liver Cancer 2013, 2:31-39.
 
18]  Taketa, K. Alfafetoprotein: reevaluation in hepatology. Hepatology 1990, 12: 1420-32.
 
19]  Tarr, AW., Urbanowicz, R A. and Ball, JK. The Role of Humoral Innate Immunity in Hepatitis C Virus Infection. Viruses 2012, 4(1): 1-27.
 
20]  Youssef, A., Yano, Y., Utsumi, T., abd El-alah, EM., abd El-HameedAel, E., SerwahAel, H., et al. Molecular epidemiological study of hepatitis viruses in Ismailia, Egypt. Intervirology 2009, 52 (3) 123-31.
 
Show Less References

Article

A Five Year Review of Cervical Cytology in Abakaliki, Nigeria

1Department of Obstetrics and Gynaecology,Federal Teaching Hospital, Abakaliki

2Department of Obstetrics and Gynaecology,University of Nigeria Teaching Hospital, Enugu

3Department of Microbiology, Ebonyi State University, Abakaliki


American Journal of Cancer Prevention. 2015, 3(2), 23-26
DOI: 10.12691/ajcp-3-2-1
Copyright © 2015 Science and Education Publishing

Cite this paper:
Leonard Ogbonna Ajah, Paul Olisaemeka Ezeonu, Nelson Chukwudi Ozonu, Chukwuemeka Anthony Iyoke, Peter Onubiwe Nkwo, Monique Iheoma Ajah. A Five Year Review of Cervical Cytology in Abakaliki, Nigeria. American Journal of Cancer Prevention. 2015; 3(2):23-26. doi: 10.12691/ajcp-3-2-1.

Correspondence to: Leonard  Ogbonna Ajah, Department of Obstetrics and Gynaecology,Federal Teaching Hospital, Abakaliki. Email: leookpanku@yahoo.com

Abstract

Background: Cervical cancer is the commonest gynecological cancer in Nigeria. The risk factors to cervical cancer are common in our environment. Objective: To determine the prevalence of cervical squamous cell abnormalities and the risk factors associated with the disease in Abakaliki, Nigeria. Methods: A 5 year retrospective study of cervical cytology at the Federal Teaching Hospital, Abakaliki from 1st January 2008 to 31st December 2012, was undertaken. Results: The prevalence of cervical squamous cell abnormalities in this study was 11.2%. These cervical squamous cell abnormalities comprised ASC-US (0.6%), LSIL (3.9%) and HSIL (6.7%). Cervical squamous cell abnormalities were significantly commoner among clients who were smokers, live in rural areas, had high parity and history of vaginal discharge/itching. However, age at coitarche, educational qualification and use of hormonal contraceptives did not have any effect on cervical squamous cell abnormality in this study. Conclusion: There is high prevalence of cervical squamous cell abnormality in Abakaliki. So there is need for public sensitization about this problem and the various ways of stemming the tide.

Keywords

References

[[[[[[[[[[[[[[[[[[[[[[[[[
[1]  Anorlu RI, Igwilo CI, Akanmu AS, Banjo AA, Odunukwe NN, Okany CC, et al. Prevalence of abnormal cervical smears among patients with HIV in Lagos, Nigeria. West Afr J Med 2007 Apr-Jun; 26 (2): 143-7.
 
[2]  Parkin DM, Ferlay J, Hamdi-Cherif M, Sitas F, Thomas JO. Cancer in Africa: Epidemiology and Prevention. IARC Scientific Publications. No. 153. Lyon: IARC Press, 2003.
 
[3]  Parkin DM, Whelan SL, Ferlay J, Teppo L and Thomas DB (editors). Cancer Incidence in Five Continents, Vol VIII. IARC Scientific Publication No. 155. Lyon: IARC, 2002.
 
[4]  Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base; Lyon, 2004.
 
[5]  World Health Organization. Nigeria:Human Papillomavirus and Related Cancers, Fact Sheet 2014. WHO/ICO HPV Information Centre. Institut Català d’Oncologia Avda. Gran Via de l’Hospitalet, 199-20308908 L’Hospitalet de Llobregat (Barcelona, Spain). e-mail: info@hpvcentre.net.internet adress: www.hpvcentre.net.
 
Show More References
6]  Galadanci HS, Mohammed AZ, Uzoho CC, Jido TA, Ochicha O. Gynaecological Malignancies Seen in a Tertiary Health Facility in Kano, Northern Nigeria. Trop J Obstet Gynaecol. 2003; 20 (2): 105-108.
 
7]  Greenlee RT, Hill-Norman MB, Murray T, Thun M. Cancer Statistics 2001. Cancer J Clin 2001; 51: 15-36
 
8]  Dim CC, Ezegwui HU, Ikeme AC, Nwagha UI, Onyedum CC. Prevalence of cervical squamous intraepithelial lesions among HIV-positive women in Enugu, South-eastern Nigeria. J Obstet Gynaecol. 2011 Nov; 31 (8): 759-62.
 
9]  Azodi M, Roy W. Premalignant lesions of the lower genital tract. In: Okonofua F,Odunsi K, editors. Contemporary Obstetrics and Gynaecology in DevelopingCountries. Benin City: Women’s Health and Action Research Center; 2003: 255-88.
 
10]  Chan MK, Wong FW. The Papanicolaou Test-Its Current Status. Hong Kong Practitioner 1990; 12. Available from: http://sunzi1.lib.hku.hk/hkjo/article.jsp?book=23&issue=230141.
 
11]  Guilbert E, Boroditsky R, Black A, Kives S, Leboeuf M, Mirosh M, et al. Canadian Consensus Guideline on Continuous and Extended Hormonal Contraception, 2007. J Obstet Gynaecol Can 2007; 29: S1-32.
 
12]  Kabir M, Iliyasu Z, abubakar IS, Mahbooh S. Awareness and Practice of Cervical Cancer Screening Among Female Health Professionals in Murtala Mohammed Specialist Hospital, Kano. Nig Post Grad Med J. 2005: 12 (3):179-182.
 
13]  Eze JN, Umeora OU, Obuna VE, Ejikeme BN. Cervical cancer awareness and cervical screening uptake at the mater Misericordiae Hospital, Afikpo, South-East Nigeria. Ann Afr Med J 2012, 11: 238-43.
 
14]  Chinaka CC, Nwazue UC. Awareness of cervical cancer and its screening in Abakaliki,Nigeria. African Journal of Cellular Pathology. 2013; 1 (1): 47-51.
 
15]  Chukwuali LI, Onuigbo WIB, Mgbor NC. Cervical cancer screening in Enugu.Trop J Obs Gyn. 2003; 20 (2): 147-154.
 
16]  Obaseki D E, Nwafor C C. Cervical Cancer Screening In Benin City, South-South Nigeria. IOSR-JDMS. 2013; 5 (1): 16-19.
 
17]  Ezechi OC, Pettersson KO, Okolo CA, Ujah IAO, Ostergren PO. The Association between HIV Infection, Antiretroviral Therapy and Cervical Squamous Intraepithelial Lesions in South Western Nigerian Women. PLoS ONE. 2014; 9 (5): e97150.
 
18]  Thomas JO; Ojemakinde KO; Ajayi IO; Omigbodun AO; Fawole OI; Oladepo O. Population-based prevalence of abnormal cervical cytology findings and local risk factors in Ibadan, Nigeria: implications for cervical cancer control programs and human papilloma virus immunization. Acta Cytol; 56 (3): 251-8, 2012.
 
19]  Pimentel VM, Jiang X, Mandavilli S, Umenyi NC, Schnatz PF. Prevalance of high risk cervical human papillomavirus and squamous intraepithelial lesions in Nigeria. J Low GenitTract Dis. 2013; 17 (2): 203-209.
 
20]  Yakasai IA, Abdullahi HM, Mohammed AZ, Galadanci H. Prevalance of cervical dysplasia among women in Kano Municipal,Kano State, Nigeria. Journal of Medicine in the Tropics. 2012; 14 (1): 64-68.
 
21]  Ahmed SA, Ayuba HU, Maiangwa A, Vakkai VI, Dashe DR, Joel R, et al. Prevalence of squamous intraepithelial lesions in Jalingo, Nigeria. African Journal of Cellular Pathology. 2013; 1:1:19-22.
 
22]  Mahmoud M, Khalida M. Prevalence of abnormal cervical smears among females in Kirkuk governorate. Journal of Kirkuk University Scientific Studies. 2012; 7 (2).
 
23]  Atilgan R, Celik A, Boztosun A, Ilter E, Yalta T, Ozercan R. Evaluation of cervical cytological abnormalities in Turkish population. Indian J Pathol Microbiol 2012; 55: 52-5.
 
24]  Bayo S, Bosch FX, de Sanjose S, Munoz N, Combita AL, Coursaget P, et al. Risk factors of invasive cervical cancer in Mali. International Journal of Epidemiology 2002; 31: 202-09.
 
25]  Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: Terminology for Reporting Results of Cervical Cytology. JAMA. 2002; 287 (16): 2114-2119.
 
26]  National Cancer Institute, surveillance epidemiology and end results. Available from: http://seer.cancer.gov/statfacts/html/cervix.html.
 
27]  National Population Commission [Nigeria] and ICF International. 2014. Nigeria Demographic and Health Survey 2013. Rockville, Maryland, USA: National Population Commission and ICF International.
 
28]  Sule ST, Shehu MS. Cervical Cancer management in Zaria, Nigeria. Afr J Health Sci. 2007; 14 (3-4): 149-153
 
29]  Fonn S,Bloch B,Madina M,Carpenter S, Cronge H,Maise C.Prevalence of pre-cancerous lesions and cervical cancer.South Afr Med J. 2002; 92 (1): 148-156.
 
30]  Franceschi S. The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Results in Cancer Research 2005; 166: 277-297.
 
Show Less References